Apogenix GmbH has raised €7.5 million from private investors to advance development of its lead product for glioblastoma. The announcement comes shortly after the company said it will investigate a new indication for the same product. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
